. 2020 Dec 15;197(9):802–811. doi: 10.1007/s00066-020-01730-9

Table 2.

Frequency of different fractionation regimens in the standard treatment arm by time in breast cancer patients (as treated)

Fractionation regimen	Total	Before S3 guideline update	After S3 guideline update	RR (95% CI) [/year (95% CI)]
Conventional fractionation with sequential boost (NF_seq)	120 (10.96%)	94 (11.33%)	26 (9.81%)	0.96 (0.88; 1.08) [0.91 (0.77; 1.07)]
Conventional fractionation with simultaneous integrated boost (NF_SIB)	605 (55.25%)	490 (59.04%)	115 (43.40%)	0.86 (0.80; 0.92) [0.90 (0.86; 0.95)]
Hypofractionation with sequential boost (HF_seq)	370 (33.79%)	246 (29.64%)	124 (46.79%)	1.21 (1.12; 1.32) [1.23 (1.14; 1.33)]

Fractionation regimen

Total

Before S3 guideline update

After S3 guideline update

RR (95% CI)
[/year (95% CI)]

Conventional fractionation with sequential boost (NF_seq)

120 (10.96%)

94 (11.33%)

26 (9.81%)

0.96 (0.88; 1.08)

[0.91 (0.77; 1.07)]

Conventional fractionation with simultaneous integrated boost (NF_SIB)

605 (55.25%)

490 (59.04%)

115 (43.40%)

0.86 (0.80; 0.92)

[0.90 (0.86; 0.95)]

Hypofractionation with sequential boost (HF_seq)

370 (33.79%)

246 (29.64%)

124 (46.79%)

1.21 (1.12; 1.32)

[1.23 (1.14; 1.33)]

Data presented as number of patients, with percentages in parentheses. Relative risk (RR) per year estimated by generalized linear model assuming binomial distribution of patients in the respective category and identical link function

RR relative risk, CI confidence interval